Amgen Inc.
$249.48B- Market cap
- $204.01B
- Debt
- +$54.60B
- Cash
- −$9.13B
Capital structure 79% equity / 21% debt · EV / Revenue 6.79x · EV proxy / EBITDA proxy 17.51x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $204.01B · View financials
Snapshot Sep 11, 2026, 4:00 PM ET
FY 2025 · Mkt cap
Decision snapshot: AMGN stock price vs INTC: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at INTC's multiple
Needs INTC P/E.
Implied fair value · at AMGN's multiple
Needs Annual EPS is negative.
Close Dec 31, 2025
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Multiple premium
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 79% equity / 21% debt · EV / Revenue 6.79x · EV proxy / EBITDA proxy 17.51x
Capital structure 80% equity / 20% debt · EV / Revenue 4.13x · EV proxy / EBITDA proxy 23.01x
AMGN carries the larger enterprise value at $249.48B against $218.44B; INTC trades on the lower EV / Revenue multiple (4.13x vs 6.79x); AMGN on the lower EV / EBITDA (17.51x vs 23.01x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Amgen Inc. · implied price per share
Bear
$121.60
Base
$161.79
Bull
$216.01
INTEL CORP · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
REGENERON PHARMACEUTICALS, INC.
AMGN vs REGN
BIOGEN INC.
AMGN vs BIIB
VERTEX PHARMACEUTICALS INC / MA
AMGN vs VRTX
Gilead Sciences, Inc.
AMGN vs GILD
Moderna, Inc.
AMGN vs MRNA
Eli Lilly and Company
AMGN vs LLY
NVIDIA Corporation
AMGN vs NVDA
QUALCOMM Incorporated
AMGN vs QCOM
Broadcom Inc.
AMGN vs AVGO
Texas Instruments Incorporated
AMGN vs TXN
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.